Population-based sequencing of the V3-loop can predict the virological response to maraviroc in treatment-naive patients of the MERIT trial.
about
A very low geno2pheno false positive rate is associated with poor viro-immunological response in drug-naïve patients starting a first-line HAARTParameters Influencing Baseline HIV-1 Genotypic Tropism Testing Related to Clinical Outcome in Patients on MaravirocReliable genotypic tropism tests for the major HIV-1 subtypesFrequent detection of CXCR4-using viruses among Brazilian blood donors with HIV-1 long-standing infection and unknown clinical stage: Analysis of massive parallel sequencing dataA genotypic HIV-1 proviral DNA coreceptor tropism assay: characterization in viremic subjects.Limited evolution of inferred HIV-1 tropism while viremia is undetectable during standard HAART therapyA randomized open-label study of 3- versus 5-drug combination antiretroviral therapy in newly HIV-1-infected individualsComplexity and dynamics of HIV-1 chemokine receptor usage in a multidrug-resistant adolescentInhibition of dual/mixed tropic HIV-1 isolates by CCR5-inhibitors in primary lymphocytes and macrophages.Covariance of charged amino acids at positions 322 and 440 of HIV-1 Env contributes to coreceptor specificity of subtype B viruses, and can be used to improve the performance of V3 sequence-based coreceptor usage prediction algorithms.Impact of HIV-1 tropism on the emergence of non-AIDS events in HIV-infected patients receiving fully suppressive antiretroviral therapy.Deep Sequencing of the HIV-1 env Gene Reveals Discrete X4 Lineages and Linkage Disequilibrium between X4 and R5 Viruses in the V1/V2 and V3 Variable Regions.Genotypic analysis of the V3 region of HIV from virologic nonresponders to maraviroc-containing regimens reveals distinct patterns of failure.Possible involvement of distinct phylogenetic clusters of HIV-1 variants in the discrepancies between coreceptor tropism predictions based on viral RNA and proviral DNA.HIV-1 tropism testing and clinical management of CCR5 antagonists: Quebec review and recommendations.Comparison of genotypic and phenotypic HIV type 1 tropism assay: results from the screening samples of Cenicriviroc Study 202, a randomized phase II trial in treatment-naive subjects.Longitudinal analysis of HIV-1 coreceptor tropism by single and triplicate HIV-1 RNA and DNA sequencing in patients undergoing successful first-line antiretroviral therapy.Determination of HIV tropism and its use in the clinical practice.Effect of HIV-1 subtype and tropism on treatment with chemokine coreceptor entry inhibitors; overview of viral entry inhibition.Results of external quality assessment for proviral DNA testing of HIV tropism in the Maraviroc Switch collaborative study.Development of maraviroc, a CCR5 antagonist for treatment of HIV, using a novel tropism assay.Genotypic tropism testing of proviral DNA to guide maraviroc initiation in aviraemic subjects: 48-week analysis of results from the PROTEST study.Comparison of population and 454 "deep" sequence analysis for HIV type 1 tropism versus the original trofile assay in non-B subtypes.RECall for automated genotypic tropism testing.Association of chemokine receptor gene variants with HIV-1 genotype predicted tropism.Issues on results of the external quality assessment for proviral DNA testing of HIV-1 tropism in the Maraviroc Switch collaborative study.HIV-1 Tropism Test Evaluation: Assessment and Clinical Implications
P2860
Q28542548-CD132D6D-41A0-415F-9AC1-CCD564423CAFQ28547216-EAE906B6-ACAA-4B73-9C6C-C61F032D2344Q30372085-31E0498D-92C6-4ECE-AF70-E56EB9F065E6Q31044033-56C3586E-AAFA-42B4-80EE-1371A8F1E510Q33712327-33688429-E16F-4C05-8374-2AC5EA2517C7Q33721466-4B913354-1FF6-4839-904E-65BDB9836A07Q34009093-3F22771E-3A80-49C3-B57D-770EFFB7BA43Q34606488-ABF5D58B-8CBE-42B3-A97F-2681D47484C3Q34846620-BFE8AC71-1641-470F-82DD-9B1CA5A2E5ACQ35330357-0459A83A-1886-42B8-957A-4FD7F5AC5DA7Q37077610-ED01CC00-4B4D-4823-977D-F7AC0BEDD9C0Q37174389-43955AEE-16B8-49E2-9152-DAD048AEFFB4Q37335890-81CF4AA0-AD01-48F5-8E8E-208379791F25Q37405921-EFA52F08-D51E-4DCB-B8C2-09080D4E90F1Q37525642-85630A32-E479-4E27-94A1-9E8E55D0CE3EQ37547823-21A7D2F9-D0EC-4257-A4BE-3956F89A084FQ37637067-CF390F62-0BCC-4E7C-9106-A912C4A75FDFQ38160078-43734BBD-5E02-4594-8E14-2C64AB95FE50Q38196457-A2C84B4C-FE25-46B3-B8E1-F6137A53F5F5Q39536633-1CC38552-2280-4918-8004-C45C4DD4A4C5Q39549270-6DB20322-FDFD-46B3-89FF-DFCFE6B5BE9DQ40390568-6A33912E-FD18-4DEC-8091-DF9828BF8DF6Q40683391-E27D50D9-52C3-42B2-9721-2B6AC25C8967Q41892522-02FA6ADC-EE19-4DC5-B129-3F77FC19236FQ42218498-778A2346-FD3A-4CDD-A5D8-F2C309150ED3Q42871904-1B738535-7152-4B2F-B8D4-BCDFD6CA7EB0Q59047721-727560C5-3F57-43B8-A189-74B2B9C067FB
P2860
Population-based sequencing of the V3-loop can predict the virological response to maraviroc in treatment-naive patients of the MERIT trial.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Population-based sequencing of ...... e patients of the MERIT trial.
@en
Population-based sequencing of ...... e patients of the MERIT trial.
@nl
type
label
Population-based sequencing of ...... e patients of the MERIT trial.
@en
Population-based sequencing of ...... e patients of the MERIT trial.
@nl
prefLabel
Population-based sequencing of ...... e patients of the MERIT trial.
@en
Population-based sequencing of ...... e patients of the MERIT trial.
@nl
P2093
P1476
Population-based sequencing of ...... e patients of the MERIT trial.
@en
P2093
Alexander Thielen
Conan K Woods
Douglass Chapman
Hernan Valdez
Jayvant Heera
Marilyn Lewis
P Richard Harrigan
Rachel A McGovern
Simon Portsmouth
P304
P356
10.1097/QAI.0B013E31826249CF
P407
P577
2012-11-01T00:00:00Z